The REDUCE pivotal trial: A prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity

Jaime Ponce, George Woodman, James Swain, Erik Wilson, Wayne English, Sayeed Ikramuddin, Eric Bour, Steven Edmundowicz, Brad Snyder, Flavia Soto, Shelby Sullivan, Richard Holcomb, John Lehmann, REDUCE Pivotal Trial Investigators

Research output: Contribution to journalArticlepeer-review

189 Scopus citations


Background Saline-filled intragastric balloon devices are reversible endoscopic devices designed to occupy stomach volume and reduce food intake. Objective: To evaluate the safety and effectiveness of a dual balloon system plus diet and exercise in the treatment of obesity compared to diet and exercise alone. Setting: Academic and community practice, United States. Methods Participants (n = 326) with body mass index (BMI) 30-40 kg/m2 were randomized to endoscopic DBS treatment plus diet and exercise (DUO, n = 187) or sham endoscopy plus diet and exercise alone (DIET, n = 139). Co-primary endpoints were a between-group comparison of percent excess weight loss (%EWL) and DUO subject responder rate, both at 24 weeks. Thereafter DUO patients had the DBS retrieved followed by 24 additional weeks of counseling; DIET patients were offered DBS treatment. Results Mean BMI was 35.4. Both primary endpoints were met. DUO weight loss was over twice that of DIET. DUO patients had significantly greater %EWL at 24 weeks (25.1% intent-to-treat (ITT), 27.9% completed cases (CC, n = 167) compared with DIET patients (11.3% ITT, P =.004, 12.3% CC, n = 126). DUO patients significantly exceeded a 35% response rate (49.1% ITT, P<.001, 54.5% CC) for weight loss dichotomized at 25%EWL. Accommodative symptoms abated rapidly with support and medication. Balloon deflation occurred in 6% without migrations. Early retrieval for nonulcer intolerance occurred in 9%. Gastric ulcers were observed; a minor device change led to significantly reduced ulcer size and frequency (10%). Conclusion The DBS was significantly more effective than diet and exercise in causing weight loss with a low adverse event profile.

Original languageEnglish (US)
Pages (from-to)874-881
Number of pages8
JournalSurgery for Obesity and Related Diseases
Issue number4
StatePublished - Jul 1 2015

Bibliographical note

Funding Information:
The Clinical Events and Data Monitoring Committee members were: Sreeni Jonnalagadda, M.D., FASGE (Chair), University of Missouri at Kansas City, Garth Jacobsen, M.D., FACS, UCSD Medical Center, Peter Denk, M.D., F.A.C.S., GI Surgical Specialists, PLLC, and Richard Chiacchierini, Ph.D., R. P. Chiacchierini & Associates, LLC. The REDUCE Pivotal Trial was supported financially by ReShape Medical. Monitoring was provided by ReShape Medical, Inc. with support from NAMSA (North American Science Associates). Statistical analysis was provided by NAMSA.

Publisher Copyright:
© 2015 American Society for Bariatric Surgery. All rights reserved.


  • Endoscopic bariatric therapy
  • Intragastric balloon
  • Nonsurgical weight loss
  • Obesity
  • Randomized controlled trial
  • Weight loss therapy


Dive into the research topics of 'The REDUCE pivotal trial: A prospective, randomized controlled pivotal trial of a dual intragastric balloon for the treatment of obesity'. Together they form a unique fingerprint.

Cite this